Dual-Fluorescence Isogenic High-Content Screening for MUC16/CA125 Selective Agents
Open Access
- 1 October 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 10 (10) , 1939-1948
Abstract
Most of the currently used cancer chemotherapies are based on compounds that inhibit general cellular mechanisms, such as DNA replication or tubulin function, and lack specificity in relation to features of the cancer cell. Recent advances in genomic studies have increased our knowledge of tumor cell biology, and a panoply of new targets have been postulated. This has provided an opportunity to develop and validate drugs that specifically target cancer cells through their unique genetic characteristics. Identification of MUC16/CA125 both as a marker and a driver of transformation led us to design a target-based high-content screen to identify and classify compounds that exhibit differential effect on MUC16-expressing cells. We developed a coculture assay in 384-well plate containing isogenic ovarian cancer cells that are positive or negative for the MUC16 protein. High-throughput screening of our small molecule pilot library led to the identification of compounds preferentially cytotoxic to MUC16+ or MUC16− cells, using a Preferential Score analysis. We compared screening results in both A2780 and SK-OV-3 ovarian cancer cells in single and coculture settings. We also identified compounds that were cytotoxic for both types of ovarian cancer cells regardless of the MUC16 status. Compounds that were preferentially targeting MUC16 cells were subsequently confirmed by caspase-induction assays. The isogenic, dual-color fluorescence strategy is an innovative approach that can effectively identify novel drug candidates, selectively targeting cancer cells that have unique molecular properties. Mol Cancer Ther; 10(10); 1939–48. ©2011 AACR.Keywords
All Related Versions
This publication has 17 references indexed in Scilit:
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- More than a biomarker: CA125 may contribute to ovarian cancer pathogenesisGynecologic Oncology, 2011
- An accelerated pathway for targeted cancer therapiesNature Reviews Drug Discovery, 2011
- Urinary levels of Bcl-2 are elevated in ovarian cancer patientsGynecologic Oncology, 2009
- Cancer genome sequencing: The challenges aheadBioEssays, 2007
- Cancer of the OvaryNew England Journal of Medicine, 2004
- Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125Clinical Cancer Research, 2004
- Is There a “Best” Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer?Journal of Clinical Oncology, 2002
- Molecular Cloning of the CA125 Ovarian Cancer AntigenJournal of Biological Chemistry, 2001
- Some Thoughts on Clinical Trials, Especially Problems of MultiplicityScience, 1977